Procedural sedation with propofol for emergency DC cardioversion.

Area of Science:

• Emergency Medicine
• Cardiology
• Anesthesiology

Background:

• Cardiac arrhythmias frequently require direct current countershock cardioversion (DCCV) in emergency settings.
• Procedural sedation is essential for DCCV, with propofol being a commonly considered agent.
• Limited evidence exists regarding propofol's optimal dosage and safety for emergency DCCV.

Purpose of the Study:

• To evaluate the safety and efficacy of propofol for procedural sedation during emergency DCCV.
• To determine appropriate propofol dosages for DCCV in patients with and without hemodynamic compromise.

Main Methods:

• Prospective case series of patients undergoing sedation-facilitated DCCV in the emergency department.
• Sedation and DCCV administered by emergency physicians.
• Adverse events monitored using the World SIVA International Sedation Task Force tool.

Main Results:

• Propofol (1 mg/kg) demonstrated safety and efficacy for DCCV in hemodynamically stable patients with atrial tachyarrhythmia.
• No moderate or sentinel adverse events were reported at this dose.
• Propofol (0.5 mg/kg) was safe for DCCV in hemodynamically compromised patients with atrial tachyarrhythmia, with no sentinel events.
• Limited evidence supports propofol use for ventricular tachycardia DCCV.

Conclusions:

• Propofol is a safe and effective agent for emergency DCCV sedation in atrial tachyarrhythmias.
• Dosage adjustments are recommended for older patients and those with hemodynamic compromise.
• Further research is needed for propofol's use in ventricular tachycardia DCCV.